Shopping Cart
- Remove All
- Your shopping cart is currently empty
Platelet aggregation-IN-3 (Compound 5) acts as a ligand for H2 histamine receptors, α2(A,C)-adrenergic receptors (α2-AR), and 5-HT2(B,C) serotonin receptors. This compound can inhibit platelet aggregation induced by ADP and collagen, and it also modulates tumor cell-induced platelet aggregation (TCIPA). Platelet aggregation-IN-3 is a promising candidate for anti-platelet therapy in cardiovascular disease and the prevention of cancer-associated thrombosis and tumor metastasis.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
10 mg | Inquiry | 10-14 weeks | |
50 mg | Inquiry | 10-14 weeks |
Description | Platelet aggregation-IN-3 (Compound 5) acts as a ligand for H2 histamine receptors, α2(A,C)-adrenergic receptors (α2-AR), and 5-HT2(B,C) serotonin receptors. This compound can inhibit platelet aggregation induced by ADP and collagen, and it also modulates tumor cell-induced platelet aggregation (TCIPA). Platelet aggregation-IN-3 is a promising candidate for anti-platelet therapy in cardiovascular disease and the prevention of cancer-associated thrombosis and tumor metastasis. |
Molecular Weight | 251.755 |
Formula | C13H18ClN3 |
Cas No. | 1029802-21-8 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.